NGEN · NASDAQ · Biotechnology

NervGen Pharma

Develops NVG-291 for spinal-cord injury.

$2.27
After-hours close0.00 (0.00%)
At close$2.27(−2.78%)
DateEstimateReportedSurprise
Nov 2026−$0.06
Aug 2026−$0.06−$0.37−510.8%
May 2026−$0.07−$0.01+80.4%
Mar 2026−$0.11−$0.26−125.8%
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Nov 12, 2026−$0.06
Aug 13, 2026−$0.06−$0.37−510.8%$4.5K
May 18, 2026−$0.07−$0.01+80.4%$4.5K
Mar 31, 2026−$0.11−$0.26−125.8%